Table 2.
Univariate and Multivariate Analysis of Predictive Factors Affecting OS and PFS
| OS | PFS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| HR | 95%CI | P-value | HR | 95%CI | P-value | HR | 95%CI | P-value | HR | 95%CI | P-value | |
| NLR (≥2.49/<2.49) | 1.890 | 1.329–2.689 | 0.000 | 1.571 | 1.093–2.259 | 0.015 | 1.388 | 1.009–1.909 | 0.044 | 1.394 | 1.012–1.919 | 0.042 |
| Age, years (≥60/<60) | 1.037 | 0.725–1.483 | 0.842 | 0.942 | 0.686–1.295 | 0.715 | ||||||
| Gender (male/female) | 0.911 | 0.552–1.502 | 0.715 | 1.070 | 0.674–1.698 | 0.774 | ||||||
| ECOGPS (1/0) | 1.276 | 0.896–1.818 | 0.177 | 0.996 | 0.728–1.364 | 0.981 | ||||||
| PLT,10^9/L (≥125/<125) | 0.967 | 0.667–1.400 | 0.858 | 0.990 | 0.712–1.376 | 0.952 | ||||||
| ALT, U/L(≥40/<40) | 1.405 | 0.987–2.000 | 0.059 | 1.470 | 1.069–2.022 | 0.018 | 1.427 | 1.037–1.964 | 0.029 | |||
| ALB, g/L(≥40/<40) | 0.356 | 0.244–0.518 | 0.000 | 0.495 | 0.331–0.741 | 0.001 | 0.724 | 0.527–0.992 | 0.045 | 0.227 | ||
| GGT, U/L (≥45/<45) | 1.986 | 1.093–3.608 | 0.024 | 0.622 | 1.597 | 0.975–2.615 | 0.063 | |||||
| TBil, umol/L (≥21/<21) | 1.900 | 1.331–2.714 | 0.000 | 1.545 | 1.064–2.242 | 0.022 | 1.356 | 0.990–1.857 | 0.058 | |||
| AFP, ng/mL(>400/≤400) | 1.176 | 0.827–1.671 | 0.368 | 1.282 | 0.936–1.755 | 0.121 | ||||||
| Tumor size, cm(>10/ ≤10) | 1.552 | 1.063–2.267 | 0.023 | 0.338 | 1.040 | 0.737–1.467 | 0.823 | |||||
| Tumor number(>3/≤3) | 1.510 | 1.057–2.159 | 0.024 | 0.490 | 1.225 | 0.896–1.674 | 0.204 | |||||
| Child-Pugh | 0.000 | 0.982 | 0.053 | |||||||||
| A | 0.431 | 0.292–0.637 | 0.698 | 0.485–1.004 | ||||||||
| B | 2.319 | 1.570–3.425 | 1.433 | 0.996–2.061 | ||||||||
| BCLC stage | 0.196 | 0.504 | ||||||||||
| B | 0.737 | 0.465–1.170 | 0.873 | 0.585–1.301 | ||||||||
| C | 1.356 | 0.854–2.153 | 1.146 | 0.769–1.708 | ||||||||
| Type of hepatitis | ||||||||||||
| None | 1.059 | 0.662–1.693 | 0.812 | 0.962 | 0.635–1.458 | 0.857 | ||||||
| HBV | 0.947 | 0.614–1.459 | 0.804 | 1.041 | 0.709–1.529 | 0.838 | ||||||
| HCV | 0.741 | 0.235–2.332 | 0.608 | 0.957 | 0.354–2.589 | 0.931 | ||||||
| Macrovascular invasion | 1.507 | 1.058–2.147 | 0.023 | 0.963 | 1.180 | 0.862–1.615 | 0.301 | |||||
| Bone metastasis | 1.232 | 0.746–2.034 | 0.414 | 1.326 | 0.828–2.124 | 0.240 | ||||||
| Extrahepatic metastasis | 0.902 | 0.633–1.286 | 0.569 | 0.945 | 0.689–1.294 | 0.723 | ||||||
| Lung metastasis | 1.067 | 0.600–1.898 | 0.825 | 1.404 | 0.835–2.360 | 0.200 | ||||||
| Lymph node metastasis | 0.879 | 0.609–1.269 | 0.491 | 0.800 | 0.578–1.107 | 0.178 | ||||||
| Prior treatment | ||||||||||||
| Surgery | 0.591 | 0.399–0.875 | 0.009 | 0.559 | 0.883 | 0.632–1.233 | 0.464 | |||||
| RFA | 0.179 | 0.078–0.409 | 0.000 | 0.192 | 0.083–0.446 | 0.000 | 0.527 | 0.318–0.876 | 0.013 | 0.544 | 0.327–0.905 | 0.019 |
| TACE or TAE | 0.969 | 0.636–1.476 | 0.883 | 1.014 | 0.696–1.477 | 0.942 | ||||||
| Radiotherapy | 1.074 | 0.438–2.635 | 0.875 | 0.906 | 0.400–2.053 | 0.814 | ||||||
Abbreviations: OS, overall survival; PFS, progression-free survival; HR, hazard ratio; 95% CI, 95% confidence interval.